Big Money trying to take control of the company before all the good news comes out, Senile Raj just setting by and letting control of the company be traded away at ever lower prices. Once they take over they will get rid of him and run the stock price up to $45 +. Too arrogant and demented to even get some positive event press releases out. He should try to save himself by starting a dementia research program. Unbelievable what he has done to his long term shareholders.
Some money being spent to protect new positions. Looks like more PBYI money coming on board for the news and a nice squeeze.
Lots of results yet to be disclosed. They alone could cause a short squeeze. Those listed are only from the NCI. There Are others ongoing in US and Around The World.
Has Results Belinostat in Treating Patients With Myelodysplastic Syndromes
Has Results Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage
not recruiting Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With
Completed PXD101 in Treating Patients With Acute Myeloid Leukemia
Completed PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the
Chest That Cannot Be Removed By Surgery.
Recruiting Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic
Active, A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and
recruiting not Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malig-
Recruiting A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With
Small Cell Lung Carcinoma and Other Advanced Cancers
Completed Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian
Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not
Respond to Carboplatin or Cisplatin
Active, Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or
not recruiting Other Diseases
Completed PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's
Has Results Lymphoma
Completed Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Twelve days have passed since Eric Scott Hunsader, the founder of Nanex, posted the definitive proof of how HFT alogo's criminally manipulate the stock market. That market changing discovery has now been amplified by two additional factors.
The first being the increasing involvement of lawyer Michael Lewis, and one of the worlds most successful law firms that sued the tobacco industry and won the Huge settlement. On May 22, 2014 a class action complaint was filed against all 13 US stock exchanges and their subsidiaries, This will no doubt be one the most significant and revealing court cases of the century. The discovery process should reveal a wealth of unbelievable long running corruption and willful failure to enforce regulations.
The second industry changing event is the offer by Eric Scott Hunsader to make the data, the methods, operational sequences and suspected computer programming code used to manipulate the stock and options market available to all, I suspect, "good side" programers for free. Twelve long day's of coding and energy drinks should begin to show up in the markets as multiple new alogo approaches from some of the most brilliant programmers on the planet try to punish the shorts as they play their "GAME".
The stocks that are heavily shorted are rarely about inside information, they are mostly low float, thinly traded LONG term investments for most shareholders. When most shares are held long you will see the large new 5-9.97% share holders move in to supply the shares shorts need to borrow. Combine a guaranteed supply of shares to borrow, the ability to see the order flow before anyone else, a powerful HFT alogo and you are a short money cash machine.
They will really get excited when they see the money flow coming from PBYI winners.
Very Strange Trading Taking Place Today. No Volume Looking Like A Pending Announcement Which Should Bring A Nice Short Squeeze.
Like no one will find out what info they traded on.
New large position being taken along with short covering before today's anticipated announcement.
Being "Knighted" is not always an honor. Thanks To Nanex
FINRA 5310. Best Execution and Interpositioning
(a)(1) In any transaction for or with a customer or a customer of another broker-dealer, a member and persons associated with a member shall use reasonable diligence to ascertain the best market for the subject security and buy or sell in such market so that the resultant price to the customer is as favorable as possible under prevailing market conditions. Among the factors that will be considered in determining whether a member has used "reasonable diligence" are:
(A) the character of the market for the security (e.g., price, volatility, relative liquidity, and pressure on available communications);
(B) the size and type of transaction;
(C) the number of markets checked;
(D) accessibility of the quotation; and
(E) the terms and conditions of the order which result in the transaction, as communicated to the member and persons associated with the member.
(2) In any transaction for or with a customer or a customer of another broker-dealer, no member or person associated with a member shall interject a third party between the member and the best market for the subject security in a manner inconsistent with paragraph (a)(1) of this Rule.
Must Be Someone Inside The Company Feeding Information Out To The Shorts. This Is The Perfect Place For Some Puma Money To Pounce.
Move Your Money To SPPI For The Next Short Squeeze, 21.7% Sold Short On Float Of 65,582,000 Shorts have been beating this down for 1 1/2 years. 3 Great drugs in near term pipeline & 9 more after that with one entering into a 6 billion dollar US market for that drug. Major trial results and FDA announcements expected very soon along with 2qtr conference call around August 6. Research and acquisition funded from cash flow.. Just started marketing it's newest drug Beleodaq, which was granted accelerated approval by FDA. 9 drug late stage development pipeline targeting individual markets of up to 6 billion per year in US. Take A Look.
13,736,837 shares sold short. 65,582,000 shares outstanding. # 10 most shorted biotech. 5 drugs on the market specializing in oncology and hematology. Research and acquisition funded from cash flow.. Just started marketing it's newest drug Beleodaq, which was granted accelerated approval by FDA. Very promising near term 3 drug pipeline and a 9 drug late stage development pipeline targeting individual markets of up to 6 billion per year in US. Take A Look.
SPPI Has A Better Game Than Puma. Sadly, The Game Has Been Taken Over By The Short Funds With Good HFT Programs. If The Word Gets Out And Some Of The Puma Rich Jump In to SPPI In The Next Couple Of Days You Could Make Your Bad Trade Good. Spectrum Has Been Controlled By Shorts But, Beleodaq And A Pfizer Buyout Offer Will Change All Of That In A Huge Way.
cbmngmt: Seeing 5 thumbs down on my positive post really inspires me to recommend that you take the largest short position you can margin your way into. PUMA winners will try for a repeat with SPPI, a much better company to play. Pawn your cars and buy some more shares to sell short.
Sell All Today. Then take half of your profit and double it by going long SPPI. Huge short squeeze will develop in next couple of days as the 10th most shorted biotech gets the attention and money from the Puma Biotechnology winners. Check out their actual profitable drug lines and their newest drug, Beleodaq that launched today. Spectrum Pharmaceuticals.website will show you why they are not a one trick pony.
SPPI #10 Most Shorted Biotech With 60 Million Float. Beleodaq, Their 5th Oncology Drug Is Launching Today.
With over 25% of shares sold short, SPPI was the number 10 most shorted biotech as last reported. After 2 years of torture by short fund HFT traders, it's time they got the attention of new investors who may have made a bunch of money today on Puma. It's marketed product lines fund drug development and acquisition with it's positive cash flow from what was the 4 oncology / hematology drugs they market. Today they launched their 5th oncology drug Beleodaq. The FDA gave it accelerated approval. Spectrum Pharmaceuticals also has 3 late stage development drugs in addition to the 9 very promising drugs being developed, some of which would be entering into a 6 billion dollar annual sales market.